Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the lining of the joints, causing pain, swelling, and progressive damage. As of 2019, roughly 18 million people worldwide were living with RA, and women are two to three times more likely to develop it than men. Unlike osteoarthritis, which results from wear and tear on cartilage, RA is driven by inflammation that can affect the entire body.
How RA Develops in the Body
In a healthy joint, the synovial membrane is a thin tissue that produces fluid to keep the joint lubricated. In RA, the immune system sends waves of inflammatory cells into this membrane, including T cells, B cells, and natural killer cells. These cells release signaling molecules, most notably TNF-alpha, IL-6, and IL-17, that amplify inflammation and recruit even more immune activity to the joint.
The damage happens on two fronts. First, specialized cells called synovial fibroblasts respond to the inflammatory signals by releasing enzymes that break down cartilage and bone tissue. Second, another type of cell called an osteoclast becomes overactive. Osteoclasts normally break down small amounts of bone so it can be rebuilt, but in RA the balance tips heavily toward destruction. The result is joint erosion, deformity, and loss of function if the disease goes unchecked.
Early Symptoms and What They Feel Like
The hallmark of RA is morning stiffness that lasts more than one hour and often persists for several hours. This is different from the brief stiffness many people feel when they first get out of bed. RA stiffness improves gradually with movement throughout the day.
The joints affected first are typically the small ones: the middle knuckles of the fingers, the knuckles at the base of the fingers, the wrists, and the small joints of the feet near the toes. A key feature is symmetry. If the knuckles on your left hand are swollen, the same knuckles on your right hand usually are too. Joints feel warm, tender, and puffy rather than just achy. Fatigue, low-grade fever, and a general sense of feeling unwell often accompany the joint symptoms, especially during flares.
Effects Beyond the Joints
RA is a systemic disease, meaning it can affect organs and tissues throughout the body. About 40 percent of people with RA develop complications outside the joints at some point. These can include firm lumps under the skin called rheumatoid nodules (often near the elbows), dry eyes and dry mouth from inflammation of moisture-producing glands, and inflammation in the lining of the lungs or heart. Blood vessel inflammation, nerve problems, and kidney involvement are less common but possible. The widespread inflammation also raises cardiovascular risk, making heart attack and stroke more likely over the long term compared to people without RA.
How RA Is Diagnosed
There is no single test that confirms RA. Doctors use a combination of physical examination, blood work, and imaging to piece together the diagnosis. The classification system used internationally scores patients across four categories, and a score of 6 or more out of 10 points to a definite diagnosis.
The four categories are:
- Joint involvement: More joints affected, especially small joints, earn more points. Having more than 10 swollen joints (with at least one small joint) scores the maximum of 5.
- Blood markers: Two key antibody tests are rheumatoid factor (RF) and anti-CCP antibodies. A strongly positive result on either scores 3 points.
- Inflammation markers: Elevated C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) adds 1 point.
- Symptom duration: Symptoms lasting 6 weeks or longer add 1 point.
Of the blood tests, anti-CCP antibodies are the more useful marker. They have a specificity above 95 percent, meaning a positive result very rarely shows up in someone who doesn’t have RA, and a positive predictive value between 90 and 98 percent. Their sensitivity is around 68 percent, so a negative result doesn’t rule RA out. Rheumatoid factor is positive in a broader range of conditions and has a positive predictive value of only about 30 percent on its own, making it less reliable when used in isolation.
Treatment Strategy
The goal of modern RA treatment is remission, or at least very low disease activity, achieved through a “treat-to-target” approach. This means your doctor sets a specific measurable target, checks your progress at regular intervals (usually every one to three months early on), and adjusts treatment if you’re not reaching it. In a large real-world study across the Asia-Pacific region, about 25 to 35 percent of patients achieved remission depending on which measurement tool was used, with some measures showing rates above 60 percent.
The first medication most people start is methotrexate, taken once a week as a pill. It works by dialing down the overactive immune response that drives joint damage. It can take several weeks to reach full effect, and doctors typically increase the dose gradually based on response. This remains the backbone of RA therapy and is often combined with other medications if needed.
Biologic and Targeted Therapies
When methotrexate alone isn’t enough, biologic medications that block specific inflammatory signals are the next step. TNF inhibitors were the first class developed and remain widely used. They work by neutralizing TNF-alpha, one of the main molecules fueling joint destruction. Other biologics target different parts of the immune cascade, including IL-6 and certain types of immune cells.
A newer class of oral medications called JAK inhibitors (tofacitinib, baricitinib, and upadacitinib) blocks inflammatory signaling inside cells rather than outside. These are generally reserved for people who haven’t responded well to a TNF inhibitor. The FDA requires these drugs to carry prominent warnings about increased risks of serious cardiovascular events, blood clots, and certain cancers including lymphoma and lung cancer. People with a history of heart problems, stroke, blood clots, or smoking face higher risk with these medications.
Why Early Treatment Matters
Joint damage from RA can begin within the first few months of disease and is largely irreversible once it occurs. The earlier aggressive treatment starts, the better the chances of preventing erosion, preserving joint function, and achieving remission. Studies consistently show that a delay of even a few months in starting disease-modifying therapy leads to worse long-term outcomes. The “window of opportunity” in the first three to six months after symptoms begin is when treatment has the greatest impact on the course of the disease.
Living with RA also means managing its ripple effects: protecting cardiovascular health through exercise and risk factor control, monitoring for lung and eye complications at regular checkups, and staying physically active to maintain joint mobility and muscle strength. Physical therapy, occupational therapy, and joint protection strategies all play a meaningful role alongside medication in keeping the disease from limiting daily life.